FdaApplication
NDA 208261
Identifiers
- fda_app_no: NDA208261
Properties
| Property | Value |
|---|---|
| applicant_name | MERCK SHARP AND DOHME LLC A SUB OF MERCK AND CO INC |
| application_type | NDA |
| approval_date | 2016-01-28 |
Revenue by product
ZEPATIER
| Period | Revenue |
|---|---|
| Q4 2020 | $45.0M* |
| Q3 2020 | $28.0M* |
| Q2 2020 | $39.0M* |
| Q1 2020 | $55.0M* |
| Q4 2019 | $66.0M* |
| Q3 2019 | $83.0M* |
| Q2 2019 | $108.0M* |
| Q1 2019 | $114.0M* |
| Q4 2018 | $108.0M* |
| Q3 2018 | $104.0M* |
| Q2 2018 | $113.0M* |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| ZEPATIER | ELBASVIR; GRAZOPREVIR | 50MG;100MG | TABLET;ORAL |
1 product